A systematic review of evidence based treatments for lichen simplex chronicus

References

• Whang KA, Kwatra SG. Gender and racial differences in patient perception of pruritus: evidence from a single institution and National Ambulatory Medical Care Survey data. J Invest Dermatol. 2018;138(5):S220.
   Web of Science ®Google Scholar
• Boozalis E, Tang O, Patel S, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol. 2018;79(4):714–719.
   PubMed Web of Science ®Google Scholar
• Huang AH, Canner JK, Khanna R, et al. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2019;140(2):480–483.
   Web of Science ®Google Scholar
• Howick JC, Iain Chalmers, Glasziou P, et al. The Oxford 2011 levels of evidence. 2011. Available from: https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/.
   Google Scholar
• Guzzo CA, Weiss JS, Mogavero HS, et al. A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses. J Am Acad Dermatol. 1991;25(6):1179–1183.
   PubMed Web of Science ®Google Scholar
• Kantor I, Cook PR, Cullen SI, et al. Double-blind bilateral paired comparison of 0.05% halobetasol propionate cream and its vehicle in patients with chronic atopic dermatitis and other eczematous dermatoses. J Am Acad Dermatol. 1991;25(6 Pt 2):1184–1186.
   PubMed Web of Science ®Google Scholar
• Datz B, Yawalkar S. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991;25(6):1157–1160.
   PubMed Web of Science ®Google Scholar
• Brunner N, Yawalkar S. A double-blind, multicenter, parallel-group trial with 0.05% halobetasol propionate ointment versus 0.1% diflucortolone valerate ointment in patients with severe, chronic atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991;25(6):1160–1163.
   PubMed Web of Science ®Google Scholar
• Rajan VS. Controlled double blind trial with supracortin cream. Singap Med J. 1976;17(4):216–218.
   Google Scholar
• Geraldez MCB, Carreon‐Gavino M, Hoppe G, et al. Diflucortolone valerate ointment with and without occlusion in lichen simplex chronicus. Int J Dermatol. 1989;28(9):603–604.
   PubMed Web of Science ®Google Scholar
• Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol. 1992;72(1):69–71.
   PubMed Web of Science ®Google Scholar
• Goldstein AT, Parneix-Spake A, McCormick CL, et al. Pimecrolimus cream 1% for treatment of vulvar lichen simplex chronicus: an open-label, preliminary trial. Gynecol Obstet Invest. 2007;64(4):180–186.
   PubMed Web of Science ®Google Scholar
• Kelekci HK, Uncu HG, Yilmaz B, et al. Pimecrolimus 1% cream for pruritus in postmenopausal diabetic women with vulvar lichen simplex chronicus: a prospective non-controlled case series. J Dermatolog Treat. 2008;19(5):274–278.
   PubMed Web of Science ®Google Scholar
• Tan E, Tey HL, Tan ES, et al. Tacrolimus ointment 0.1% in the treatment of scrotal lichen simplex chronicus: an open-label study. Ann Acad Med Singap. 2013;42(9):S284.
   Google Scholar
• Kantor GR, Resnik KS. Treatment of lichen simplex chronicus with topical capsaicin cream. Acta Derm Venereol. 1996;76(2):161
   PubMed Web of Science ®Google Scholar
• Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. Arch Dermatol. 1995;131(12):1403–1408.
   PubMedGoogle Scholar
• Breneman DL, Dunlap FE, Monroe EW, et al. Doxepin cream relieves eczema-associated pruritus within 15 min and is not accompanied by a risk of rebound upon discontinuation. J Dermatol Treat. 1997;8(3):161–168.
   Web of Science ®Google Scholar
• Yosipovitch G, Sugeng MW, Chan YH, et al. The effect of topically applied aspirin on localized circumscribed neurodermatitis. J Am Acad Dermatol. 2001;45(6):910–913.
   PubMed Web of Science ®Google Scholar
• Gencoglan G, Inanir I, Gunduz K. Therapeutic hotline: treatment of prurigo nodularis and lichen simplex chronicus with gabapentin. Dermatol Ther. 2010;23(2):194–198.
   PubMed Web of Science ®Google Scholar
• Sanjana VD, Fernandez RJ. Evaluation of an antihistamine and antidepressant for the treatment of lichen simplex chronicus. Indian J Dermatal Venereol Leprol. 1992;58(6):384–387.
   Google Scholar
• Esen Salman K, Kivanc AI, Salman A. The efficacy and safety of targeted narrowband UVB therapy: a retrospective cohort study. Turk J Med Sci. 2019;49(2):595–603.
   PubMed Web of Science ®Google Scholar
• Greaves MW. Recent advances in pathophysiology and current management of itch. Ann Acad Med Singap. 2007;36(9):788–792.
   PubMed Web of Science ®Google Scholar
• Monk BE. Transcutaneous electronic nerve stimulation in the treatment of generalized pruritus. Clin Exp Dermatol. 1993;18(1):67–68.
   PubMed Web of Science ®Google Scholar
• Engin B, Tufekci O, Yazici A, et al. The effect of transcutaneous electrical nerve stimulation in the treatment of lichen simplex: a prospective study. Clin Exp Dermatol. 2009;34(3):324–328.
   PubMed Web of Science ®Google Scholar
• Mohammad Ali BM, Hegab DS, El Saadany HM. Use of transcutaneous electrical nerve stimulation for chronic pruritus. Dermatol Ther. 2015;28(4):210–215.
   PubMed Web of Science ®Google Scholar
• Yuksek J, Sezer E, Aksu M, et al. Transcutaneous electrical nerve stimulation for reduction of pruritus in macular amyloidosis and lichen simplex. J Dermatol. 2011;38(6):546–552.
   PubMed Web of Science ®Google Scholar
• Wu C, Zou M, Xiong Y, et al. Short- and long-term efficacy of focused ultrasound therapy for non-neoplastic epithelial disorders of the vulva. BJOG. 2017;124:87–92.
   PubMed Web of Science ®Google Scholar
• Matsuda KM, Sharma D, Schonfeld AR, et al. Gabapentin and pregabalin for the treatment of chronic pruritus. J Am Acad Dermatol. 2016;75(3):619–625.e6.
   PubMed Web of Science ®Google Scholar
• Sharma D, Kwatra SG. Thalidomide for the treatment of chronic refractory pruritus. J Am Acad Dermatol. 2016;74(2):363–369.
   PubMed Web of Science ®Google Scholar
• He A, Alhariri JM, Sweren RJ, et al. Aprepitant for the treatment of chronic refractory pruritus. BioMed Res Int. 2017;2017:1–6.
   Web of Science ®Google Scholar
• Kwatra SG, Ständer S, Kang H. PD-1 Blockade-induced pruritus treated with a mu-opioid receptor antagonist. N Engl J Med. 2018;379(16):1578–1579.
   PubMed Web of Science ®Google Scholar